Feb 1, 2026
How do baseline tau PET levels modify the effect of amyloid‑lowering antibodies on clinical decline?
Baseline measured by strongly modifies how much clinical benefit patients derive from amyloid‑lowering antibodies: lower neocortical tau at baseline associates with larger slowing of cognitive decline...